These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 37935564)

  • 21. Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study.
    Sanchez A; Furberg H; Kuo F; Vuong L; Ged Y; Patil S; Ostrovnaya I; Petruzella S; Reising A; Patel P; Mano R; Coleman J; Russo P; Liu CH; Dannenberg AJ; Chan TA; Motzer R; Voss MH; Hakimi AA
    Lancet Oncol; 2020 Feb; 21(2):283-293. PubMed ID: 31870811
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In silico DNA methylation analysis identifies potential prognostic biomarkers in type 2 papillary renal cell carcinoma.
    Yang M; Hlady RA; Zhou D; Ho TH; Robertson KD
    Cancer Med; 2019 Sep; 8(12):5760-5768. PubMed ID: 31361072
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An Empirical Approach Leveraging Tumorgrafts to Dissect the Tumor Microenvironment in Renal Cell Carcinoma Identifies Missing Link to Prognostic Inflammatory Factors.
    Wang T; Lu R; Kapur P; Jaiswal BS; Hannan R; Zhang Z; Pedrosa I; Luke JJ; Zhang H; Goldstein LD; Yousuf Q; Gu YF; McKenzie T; Joyce A; Kim MS; Wang X; Luo D; Onabolu O; Stevens C; Xie Z; Chen M; Filatenkov A; Torrealba J; Luo X; Guo W; He J; Stawiski E; Modrusan Z; Durinck S; Seshagiri S; Brugarolas J
    Cancer Discov; 2018 Sep; 8(9):1142-1155. PubMed ID: 29884728
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Papillary renal cell carcinoma: a clinicopathological and whole-genome exon sequencing study.
    Liu K; Ren Y; Pang L; Qi Y; Jia W; Tao L; Hu Z; Zhao J; Zhang H; Li L; Yue H; Han J; Liang W; Hu J; Zou H; Yuan X; Li F
    Int J Clin Exp Pathol; 2015; 8(7):8311-35. PubMed ID: 26339402
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic and prognostic tissuemarkers in clear cell and papillary renal cell carcinoma.
    Kroeze SG; Bijenhof AM; Bosch JL; Jans JJ
    Cancer Biomark; 2010; 7(6):261-8. PubMed ID: 21694464
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma.
    Brown LC; Zhu J; Desai K; Kinsey E; Kao C; Lee YH; Pabla S; Labriola MK; Tran J; Dragnev KH; Tafe LJ; Dayyani F; Gupta RT; McCall S; George DJ; Glenn ST; Nesline MK; George S; Zibelman M; Morrison C; Ornstein MC; Zhang T
    J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36252996
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genomic profiling of renal cell carcinoma in patients with end-stage renal disease.
    Inoue T; Matsuura K; Yoshimoto T; Nguyen LT; Tsukamoto Y; Nakada C; Hijiya N; Narimatsu T; Nomura T; Sato F; Nagashima Y; Kashima K; Hatakeyama S; Ohyama C; Numakura K; Habuchi T; Nakagawa M; Seto M; Mimata H; Moriyama M
    Cancer Sci; 2012 Mar; 103(3):569-76. PubMed ID: 22145865
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of a claudin-low subtype in clear cell renal cell carcinoma with implications for the evaluation of clinical outcomes and treatment efficacy.
    Zhang C; Li Y; Qian J; Zhu Z; Huang C; He Z; Zhou L; Gong Y
    Front Immunol; 2022; 13():1020729. PubMed ID: 36479115
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cuproptosis-related modification patterns depict the tumor microenvironment, precision immunotherapy, and prognosis of kidney renal clear cell carcinoma.
    Cai Z; He Y; Yu Z; Hu J; Xiao Z; Zu X; Li Z; Li H
    Front Immunol; 2022; 13():933241. PubMed ID: 36211378
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Integrative Analysis of Immune-Related Genes in the Tumor Microenvironment of Renal Clear Cell Carcinoma and Renal Papillary Cell Carcinoma.
    Zheng B; Xie F; Cheng F; Wang J; Yao Z; He W; Niu Z
    Front Mol Biosci; 2021; 8():760031. PubMed ID: 34888353
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multidimensional Analyses of Tumor Immune Microenvironment Reveal the Possible Rationality of Immunotherapy and Identify High Immunotherapy Response Subtypes for Renal Papillary Cell Carcinoma.
    Wei B; Yu M; Yao J; Jiang M; An J; Yang J; Lin J; Zhao Y; Zhu Y
    Front Immunol; 2021; 12():657951. PubMed ID: 34531849
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative real-world survival outcomes of metastatic papillary and clear cell renal cell carcinoma treated with immunotherapy, targeted therapy, and combination therapy.
    Riveros C; Ranganathan S; Xu J; Chang C; Kaushik D; Morgan M; Miles BJ; Muhammad T; Anis M; Aghazadeh M; Zhang J; Efstathiou E; Klaassen Z; Brooks MA; Rini B; Wallis CJD; Satkunasivam R
    Urol Oncol; 2023 Mar; 41(3):150.e1-150.e9. PubMed ID: 36610815
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identifying biomarkers of papillary renal cell carcinoma associated with pathological stage by weighted gene co-expression network analysis.
    He Z; Sun M; Ke Y; Lin R; Xiao Y; Zhou S; Zhao H; Wang Y; Zhou F; Zhou Y
    Oncotarget; 2017 Apr; 8(17):27904-27914. PubMed ID: 28427189
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of HSP 90 is associated with potent anti-tumor activity in Papillary Renal Cell Carcinoma.
    Pahwa R; Dubhashi J; Singh A; Jailwala P; Lobanov A; Thomas CJ; Ceribelli M; Wilson K; Ricketts CJ; Vocke CD; Wells C; Bottaro DP; Linehan WM; Neckers L; Srinivasan R
    J Exp Clin Cancer Res; 2022 Jun; 41(1):208. PubMed ID: 35754026
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A construction and comprehensive analysis of ceRNA networks and infiltrating immune cells in papillary renal cell carcinoma.
    Fan Y; Dai F; Yuan M; Wang F; Wu N; Xu M; Bai Y; Liu Y
    Cancer Med; 2021 Nov; 10(22):8192-8209. PubMed ID: 34598322
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dismantling papillary renal cell carcinoma classification: The heterogeneity of genetic profiles suggests several independent diseases.
    Marsaud A; Dadone B; Ambrosetti D; Baudoin C; Chamorey E; Rouleau E; Lefol C; Roussel JF; Fabas T; Cristofari G; Carpentier X; Michiels JF; Amiel J; Pedeutour F
    Genes Chromosomes Cancer; 2015 Jun; 54(6):369-82. PubMed ID: 25820192
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial.
    Feldman DR; Ged Y; Lee CH; Knezevic A; Molina AM; Chen YB; Chaim J; Coskey DT; Murray S; Tickoo SK; Reuter VE; Patil S; Xiao H; Aghalar J; Apollo AJ; Carlo MI; Motzer RJ; Voss MH
    Cancer; 2020 Dec; 126(24):5247-5255. PubMed ID: 32975815
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Checkpoint inhibitors in metastatic papillary renal cell carcinoma.
    de Vries-Brilland M; McDermott DF; Suárez C; Powles T; Gross-Goupil M; Ravaud A; Flippot R; Escudier B; Albigès L
    Cancer Treat Rev; 2021 Sep; 99():102228. PubMed ID: 34111642
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Functional enrichment analysis of LYSET and identification of related hub gene signatures as novel biomarkers to predict prognosis and immune infiltration status of clear cell renal cell carcinoma.
    Chen Y; He J; Jin T; Zhang Y; Ou Y
    J Cancer Res Clin Oncol; 2023 Dec; 149(18):16905-16929. PubMed ID: 37740762
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comprehensive insights on pivotal prognostic signature involved in clear cell renal cell carcinoma microenvironment using the ESTIMATE algorithm.
    Luo J; Xie Y; Zheng Y; Wang C; Qi F; Hu J; Xu Y
    Cancer Med; 2020 Jun; 9(12):4310-4323. PubMed ID: 32311223
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.